Kiniksa (KNSA) PT Raised to $44 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
September 15, 2018 8:00 AM EDT- Single-doses were well-tolerated and showed reduction in pruritus -
- Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis -
HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented... More
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
September 15, 2018 8:00 AM EDT- Single-doses were well-tolerated and showed reduction in pruritus -
- Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis -
HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented Phase 1a/1b... More

